作者: Paul Calès , Fabrice Lainé , Jérôme Boursier , Yves Deugnier , Valérie Moal
DOI: 10.1016/J.JHEP.2008.07.035
关键词: Gastroenterology 、 Chronic liver disease 、 Liver biopsy 、 Hepatic fibrosis 、 Fatty liver 、 Population 、 Internal medicine 、 Biopsy 、 FIBROMETER 、 Medicine 、 Body mass index
摘要: Background/Aims To compare blood tests of liver fibrosis specific for NAFLD: the FibroMeter NAFLD and score (NFSA) with a non-specific test, APRI. Methods Two hundred thirty-five patients Metavir staging markers from two independent centres were randomly assigned to test ( n =121) or validation population =114). Results The highest accuracy – 91% significant was obtained whose (i) AUROC (0.943) significantly higher than those NFSA (0.884, p =0.008) APRI (0.866, −3 ; =0.309 vs NFSA) in whole population, (ii) misclassification rate (9%) lower (14%, =0.04) (16%, =0.002) did not vary according centre (14 7%, =0.07), unlike (25 9%, =0.001) (29 11%, ). By using thresholds 90% predictive values, biopsy could have been avoided most patients: FibroMeter: 97.4% NFSA: 86.8% ) APRI: 80.0% A new classification provided three reliable diagnosis intervals: F0/1, F0/1/2, F2/3/4 91.4% FibroMeter, avoiding all patients. Conclusions had high performance fibrosis, outperforming